Amubarvimab, previously known as BRII-196 , represents a noteworthy advancement in biopharmaceutical development, particularly concerning its capacity to inhibit COVID-19. This monoclonal agent demonstrates https://socialmediainuk.com/story27209009/amubarvimab-a-deep-dive-into-brii-196-s-potential